Retatrutide, tirzepatide, and semaglutide are three GLP-1 class research peptides that have generated significant interest in metabolic research over the past several years. While all three target the GLP-1 receptor, they differ substantially in their receptor profiles, structural characteristics, and research applications. This comparison is provided for laboratory reference purposes only. All compounds discussed are supplied for research use only and are not intended for human use.
Overview of the Three Compounds
Semaglutide (GLP1-S, CAS 910463-68-2) is a 31 amino acid GLP-1 receptor agonist analog developed as a structural modification of native GLP-1. Its C-18 fatty acid chain enables albumin binding, extending its half-life in research models compared to native GLP-1. As a single receptor agonist targeting only GLP-1R, semaglutide serves as the standard reference compound for isolating GLP-1 receptor-specific effects in comparative research.
Tirzepatide (GLP2-T, CAS 2023788-19-2) is a 39 amino acid dual agonist targeting both GLP-1 and GIP receptors simultaneously. Its C-20 fatty diacid modification similarly enables albumin binding. The addition of GIP receptor activity alongside GLP-1R produces distinct metabolic effects in preclinical models compared to single GLP-1 agonists, making tirzepatide a key compound for dual incretin pathway research.
Retatrutide (GLP3-R, CAS 2381089-83-2) is a 39 amino acid triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. This triple receptor profile represents the most expansive incretin receptor coverage of the three compounds and distinguishes it from both single and dual agonists. Retatrutide is studied as a reference compound for multi-receptor incretin biology and comparative pharmacology research.
Receptor Target Comparison
The fundamental difference between the three compounds is their receptor target profile:
| Compound | GLP-1R | GIPR | GCGR | Agonist Type |
|---|---|---|---|---|
| Semaglutide | ✅ | ❌ | ❌ | Single |
| Tirzepatide | ✅ | ✅ | ❌ | Dual |
| Retatrutide | ✅ | ✅ | ✅ | Triple |
This progressive expansion of receptor targets is the primary variable in comparative studies using these compounds. Laboratories studying incretin receptor biology frequently use all three as reference compounds to isolate receptor-specific contributions to downstream signaling effects.
Structural Characteristics
All three compounds share the GLP-1 receptor agonist pharmacophore as their foundation but differ in length, sequence, and modification strategy.
Semaglutide’s two structural modifications from native GLP-1 — a position 8 amino acid substitution and the C-18 fatty acid chain — provide DPP-4 resistance and albumin binding. Its 31 amino acid length is shorter than the other two compounds.
Tirzepatide’s 39 amino acid sequence incorporates a GIP-based scaffold with GLP-1 receptor binding capability engineered in. The C-20 fatty diacid modification provides albumin binding similar to semaglutide but with a longer fatty acid chain. The dual receptor engagement is achieved through a single molecule rather than a mixture of two separate peptides.
Retatrutide’s 39 amino acid sequence achieves triple receptor agonism through careful structural engineering. Its C-18 fatty diacid modification enables albumin binding while maintaining activity across all three receptor targets. The glucagon receptor component adds a metabolic dimension not present in the other two compounds.
Molecular Specifications
| Parameter | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| CAS Number | 910463-68-2 | 2023788-19-2 | 2381089-83-2 |
| Amino Acids | 31 | 39 | 39 |
| Molecular Weight | 4,113.6 g/mol | 4,813.5 g/mol | 4,731.33 g/mol |
| Receptor Targets | GLP-1R | GLP-1R, GIPR | GLP-1R, GIPR, GCGR |
| Fatty Acid Chain | C-18 | C-20 | C-18 |
Research Applications by Compound
Semaglutide is primarily used in research contexts where isolated GLP-1 receptor activation is the experimental variable. This includes GLP-1R binding kinetics, cAMP signaling cascade studies, beta cell function research, and as a single-agonist control in comparative incretin studies. Its well-characterized pharmacology makes it a foundational reference compound.
Tirzepatide is used in research contexts examining dual incretin receptor biology. Studies using tirzepatide alongside semaglutide can isolate the additive contribution of GIP receptor co-activation to downstream metabolic effects. It is particularly relevant for laboratories studying GIP/GLP-1 receptor crosstalk and synergistic incretin signaling.
Retatrutide is used in research contexts where the complete incretin receptor profile — including glucagon receptor activity — is the experimental focus. The glucagon receptor component introduces hepatic glucose output modulation and energy expenditure signaling not present in the other two compounds. Comparative studies using all three compounds can systematically isolate GLP-1R, GIPR, and GCGR contributions to metabolic outcomes.
Purity and Quality Standards
All three compounds are available from Nextday Peptides at ≥99% HPLC verified purity with lot-specific Certificates of Analysis. Each COA includes HPLC chromatogram data, mass spectrometry molecular weight confirmation, synthesis date, and lot number for full laboratory documentation compliance.
Research applications requiring quantitative comparisons between the three compounds benefit from consistent purity standards across all reference compounds. Using research-grade peptides from the same supplier with matching quality documentation reduces inter-supplier variability as a confounding variable.
Sourcing for Research Use
All three compounds are designated for research use only. They are not approved for human or animal consumption, are not pharmaceutical products, and are not intended for diagnostic or therapeutic application.
- Semaglutide Research Peptide (GLP1-S) — GLP-1R single agonist, CAS 910463-68-2
- Tirzepatide Research Peptide (GLP2-T) — GLP-1R/GIPR dual agonist, CAS 2023788-19-2
- Retatrutide Research Peptide (GLP3-R) — GLP-1R/GIPR/GCGR triple agonist, CAS 2381089-83-2
Frequently Asked Questions
What is the main difference between semaglutide, tirzepatide, and retatrutide? The primary difference is their receptor target profile. Semaglutide targets only GLP-1R. Tirzepatide targets GLP-1R and GIPR. Retatrutide targets GLP-1R, GIPR, and GCGR. Each additional receptor target adds a distinct dimension to the compound’s effects in research models.
Which compound is used as a reference standard for GLP-1 receptor research? Semaglutide is typically used as the GLP-1R reference standard due to its selective single-receptor profile and extensive characterization in published literature. Tirzepatide and retatrutide are used when dual or triple receptor effects are the research focus.
Can these compounds be used in the same study for comparison? Yes. Comparative studies using semaglutide, tirzepatide, and retatrutide alongside each other allow researchers to systematically isolate the contributions of each receptor target to observed outcomes. All three are available at matching ≥99% HPLC purity from Nextday Peptides for consistent comparative research.
Are these compounds approved for human use? No. All three are supplied for laboratory research use only and are not approved for human or animal consumption, diagnostic use, or therapeutic application.
Where can I source research-grade semaglutide, tirzepatide, and retatrutide? Nextday Peptides supplies all three compounds at ≥99% HPLC purity with lot-specific COA documentation and fast US shipping from domestic warehouses.
For research use only. Not for human or animal consumption. Not intended for diagnostic or therapeutic use. All information is provided for educational and research reference purposes only.
